Abstract
Complete surgical resection is the potentially curative treatment for pancreatic cancer, but only fewer than 20% of those individuals will be found to be eligible for surgery. Here we report a 49-year-old man with locally advanced pancreatic cancer successfully treated with high-dose radiotherapy using helical tomotherapy (66 Gy/33 fractions, 2 Gy per day over 6.5 weeks). To our knowledge, this is the first reported case of locally advanced pancreatic cancer curatively treated with helical tomotherapy alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013 CA. Cancer J Clin 63:11–30
Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165:68–72
Ji JS, Han CW, Jang JW et al (2010) Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer. Radiat Oncol 5:60. https://doi.org/10.1186/1748-717X-5-60
Callery MP, Chang KJ, Fishman EK et al (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727–1733
Zschaeck S, Blumke B, Wust P et al (2017) Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: dose volume analysis, toxicity and outcome of 28 consecutive patients. PLoS One 12:e0186341
Crane CH (2016) Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer. J Radiat Res 57(Suppl 1):i53–i57
de Geus SWL, Eskander MF, Kasumova GG et al (2017) Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer 123:4158–4167
Taylor R, Opfermann K, Jones BD et al (2012) Comparison of radiation treatment delivery for pancreatic cancer: Linac intensity-modulated radiotherapy versus helical tomotherapy. J Med Imaging Radiat Oncol 56:332–337
Chang JS, Wang ML, Koom WS et al (2012) High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 83:1448–1454
Neoptolemos JP, Stocken DD, Dunn JA et al (2001) European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234:758–768
Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
About this article
Cite this article
Hama, Y. Locally advanced pancreatic cancer successfully treated with high-dose helical tomotherapy. Int Canc Conf J 7, 152–155 (2018). https://doi.org/10.1007/s13691-018-0340-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-018-0340-3